Why is divalproex (valproate) now recommended as a mood stabilizer for an elderly patient with chronic kidney disease and porphyria, given earlier advice to avoid it in porphyria?

I Cannot Recommend Divalproex for Porphyria - This Appears to Be a Misunderstanding

I need to clarify an important point: divalproex (valproate) should NOT be used in acute hepatic porphyrias (AIP, VP, HCP, ADP) as it can precipitate life-threatening acute attacks. If I previously recommended divalproex for a patient with porphyria, that was an error that needs immediate correction.

Critical Distinction: Type of Porphyria Matters

The evidence shows a crucial difference:

Acute Hepatic Porphyrias (CONTRAINDICATED)

• Divalproex is porphyrinogenic and dangerous in acute intermittent porphyria (AIP), variegate porphyria (VP), hereditary coproporphyria (HCP), and ALA dehydratase deficiency porphyria 12
• These patients require strict avoidance of porphyrinogenic drugs to prevent potentially fatal neurovisceral attacks
• The FDA labeling does not explicitly list porphyria as a contraindication, but clinical practice guidelines universally recognize this risk

Porphyria Cutanea Tarda (SAFE)

• Valproate is safe and effective in porphyria cutanea tarda (PCT), which is NOT an acute porphyria 3
• PCT is a non-acute, cutaneous porphyria with a completely different pathophysiology
• One case report demonstrated that valproate successfully treated seizures in a PCT patient while clinical signs and biochemical abnormalities of PCT actually improved 3

The Correct Approach for Your Patient

If your patient has an acute hepatic porphyria (AIP, VP, HCP):

• Divalproex is absolutely contraindicated
• Alternative mood stabilizers must be used, though options are extremely limited
• Gabapentin and vigabatrin are considered safer anticonvulsants in acute porphyrias, though data for mood stabilization is limited

If your patient has porphyria cutanea tarda:

• Divalproex can be safely used 3
• This is the only scenario where valproate and porphyria can coexist

Additional Concerns in Your Clinical Scenario

Chronic Kidney Disease

Even if porphyria were not an issue, valproate carries significant renal risks that are particularly concerning in elderly patients with pre-existing CKD:

• Valproate can cause renal tubular dysfunction, especially in bedridden patients with low serum carnitine and phosphorus levels 4
• However, lithium poses a substantially higher CKD risk (adjusted OR 1.76) compared to valproate (adjusted OR 1.03) in elderly patients 5
• Patients with acute hepatic porphyrias are already at high risk for progressive CKD, with 29-68% developing chronic kidney disease 6

Elderly Patient Considerations

The FDA labeling specifically warns about valproate in elderly patients 7:

• Significantly higher rates of somnolence, dehydration, and nutritional decline
• Lower starting doses required (often <250mg, necessitating delayed-release formulation)
• More frequent monitoring of fluid/nutritional intake mandatory

My Recommendation

I cannot and will not recommend divalproex for a patient with acute hepatic porphyria, regardless of other comorbidities. The risk of precipitating a potentially fatal acute porphyric crisis outweighs any potential benefit for mood stabilization.

You must clarify which specific type of porphyria your patient has:

• If acute hepatic porphyria: Seek expert consultation from a porphyria specialist immediately for alternative mood stabilizer options
• If porphyria cutanea tarda: Divalproex can be considered, with careful monitoring for renal function and elderly-specific adverse effects 773

If there was a previous recommendation for divalproex in acute porphyria, that recommendation must be withdrawn immediately as it could result in serious patient harm.